New Trial: SI-6603 for Lumbar Disc Herniation

SiteRx is excited to announce the launch of a new clinical research study on our platform: SI-6603, a large Phase III trial led by Seikagaku Corporation, a global musculoskeletal and ophthalmic focused sponsor with a 70+ year track record in clinical research.

SI-6603 Study Details

A summary briefing on our latest clinical research offering

SI-6603 Study Highlights

- **Large scale, global study** - Enrollment target of 320, with immediate need for well over 200 patients
- **Broad applicability** - core criteria for enrollment is a full lumbar disc herniation

Best Practices for SiteRx Patient Recruitment

- **Discuss clinical research with your patients** - SiteRx patients are 20% more likely to participate in research if the topic is mentioned by their treating physician
- **Seamlessly refer suggested matches** - SI-6603 is one of a number of new trials debuting on the SiteRx platform in coming months

Key Inclusion Criteria

- Radiculopathy/radicular leg pain in the unilateral leg for 6 weeks or more but 1 year or less.
- Positive result of Straight Leg Raise (SLR) test (≤70°) only on the ipsilateral leg having chief complaint of radiculopathy.
- Age range of 30 - 70
- Inadequate improvement in pain caused by LDH despite 6 weeks or more of conservative treatment.

Key Exclusion Criteria

- 2 or more lumbar disc herniations.
- Undergone a lumbar operation.
- Received block procedure for treatment of LDH, oral or injectable corticosteroids within 28 days prior to randomization.
- Body mass index ≥ 40.

Questions on SI-6603? Contact your SiteRx sales or customer success representative to learn more.

Immediate Patient Need

200+

SI-6603 is among the largest actively recruiting lumbar disc herniation studies globally

Patient Site Options

50+

SiteRx is launching SI-6603 at dozens of sites in each of our core geographies, providing maximum convenience to interested patients